Trial Profile
A Phase 3, Double-Blind, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 28 Feb 2017
Price :
$35
*
At a glance
- Drugs Azilsartan (Primary) ; Olmesartan medoxomil
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 09 Apr 2015 New trial record